Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Georgia Bard's Corner -- Ignore unavailable to you. Want to Upgrade?

To: Jeff who wrote (3633)	7/11/1998 9:39:00 PM
From: out_of_the_loop	Read Replies (1) \| Respond to of 9440

"funding is now in place for animal testing " does not = news. "News" would be that the animal testing worked. "NEWS!!!" would be that it worked well, and without side effects, and that human trials were approved. JMO, I know you asked Gary but in a medical stock there is no advantage until the animal model works and human testing is complete. Next, there is FDA approval. That one piqued my interest because Japanese investigators have been working on blood substitutes for years. Unquestionably, if a blood substitute (won't abbreviate as"BS", though) that works comes to pass, it will be h$u$g$e. Technically they are substitutes for red cell transfusions given only for low hemoglobin, not for the many other things (clotting, infection-fighting, etc.) blood does.